Equity Details
Price & Market Data
Price: $42.50
Daily Change: -$0.64 / 1.51%
Daily Range: $42.28 - $44.00
Market Cap: $6,512,175,616
Daily Volume: 2,382,780
Performance Metrics
1 Week: 17.84%
1 Month: 25.90%
3 Months: 45.98%
6 Months: 31.95%
1 Year: 21.58%
YTD: 42.70%
About TG Therapeutics, Inc. (TGTX)
Understand the dynamics of TG Therapeutics, Inc. (TGTX). The stock is at 42.50, showing a -$0.64 / 1.51% change today. Market cap: 6,512,175,616. Performance over 1-week (17.84%) and 3-month (45.98%) periods are highlighted.
Company Details
Employees: 399
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.